Sacubitril/valsartan, sold under the brand name Entresto among others, is a combination drug for use in heart failure. LCZ696 (sacubitril/valsartan) is a member of a new class of agents called angiotensin receptor-neprilysin inhibitors (ARNIs) which combine a neprilysin inhibitor and angiotensin receptor blocker (ARB).  LCZ696 (Entresto™, Novartis) is a first-in-class angiotensin II receptor-neprilysin inhibitor (ARNI) whose multimodal mode of action involves neprilysin inhibition and AT1 receptor blockade. Sacubitril/valsartan (formerly known as LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor (ARNI) that simultaneously suppresses RAAS. To assess benefits and harms of first-in-class angiotensin receptor-neprilysin inhibitor sacubitril/valsartan (LCZ696) as compared to. The objectives are as follows: To assess benefits and harms of first‐in‐class angiotensin receptor‐neprilysin inhibitor sacubitril/valsartan (LCZ696).